Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD3 Protein - A hot target for bispecific antibody

CD3 Proteins-Hot target for bispecific antibody

CD3 Proteins
Background

T cell bispecific antibodies (TCBs) are molecules that are engineered to include binding sites to the T cell receptor (TCR) and to tumor-associated or tumor-specific antigens within a single entity. One of the most widely studied TCBs in cancer immunotherapy is CD3, a molecule that has the function of stabilizing TCR structure and transmitting activation signals.

Antibodies against CD3 molecules can stimulate or block T cell activation signal transduction. In addition, these antibodies can eliminate effector T cells or induce a regulatory phenotype in T cells thus, providing a new method for the treatment of organ transplant rejection and autoimmune diseases. These CD3 molecules bind to TCR non-covalently to form a TCR/CD3 receptor complex on the surface of the T cell.

There are 4 subtypes of CD3, including CD3δ, CD3ε, CD3γ, and CD3ζ. CD3δ/CD3ε and CD3γ/CD3ε can form the TCR-CD3 complexes through the α/β chain of TCR as heterodimers. CD3-targeted therapeutic antibody usually recognizes the CD3ε in the heterodimer complex to activate the anti-tumor activity of T cells. However, in the process of recombinant expression, CD3ε and CD3δ can randomly form incorrect heterogeneous complexes, which may lead to the loss of bioactivity and high batch-to-batch inconsistency.

To accelerate the research and development of bispecific antibodies, ACROBiosystems has developed a series of homogeneous CD3δ/CD3ε and CD3γ/CD3ε proteins with high bioactivity. These proteins are verified as a 1:1 heterodimer by nonreductive electrophoresis and MALS respectively. In addition, customer data suggests that bispecific antibody products from ACROBiosystems can be used in applications including, but not limited to clinical pharmacokinetics, therapeutic antibody screening, identification, and characterization.

Successively, our superior CD3 product quality helped accelerate the clinical development of a bispecific antibody into a therapeutic. Click here to download CD3 poster.

Product Features

Larger product catalog

5 molecules: CD3ε& CD3δ, CD3ε& CD3γ, CD3ε, CD3δ, CD3γ

Various tags: His, His&Avi, Fc, Llama Fc, Flag

Various species: Human, Mouse, Cynomolgus, Rat, Rabbit

Homogeneous structure: CD3ε& CD3δ and CD3ε& CD3γ are verified as 1:1 heterodimers by non-reductive electrophoresis and MALS

High bioactivity verified by binding with common antibodies such as OKT3, SP34-2, UCHT1 and BCMA×CD3

High batch-to-batch consistency guaranteed by strict quality control

Suitable for different applications including antibody immunotiter detection, biopanning, antibody screening, affinity characterization and clinical pharmacokinetic assay

Product List
  • CD3E & CD3D

  • CD3E & CD3G

  • CD3 epsilon

  • CD3 delta

  • CD3 gamma

MoleculeCat. No.SpeciesProduct DescriptionStructure
MoleculeCat. No.HostProduct DescriptionStructure
MoleculeCat. No.HostProduct DescriptionStructure
MoleculeCat. No.HostProduct DescriptionStructure
MoleculeCat. No.HostProduct DescriptionStructure
More BsAb targets

Click the molecule to find out your interesting products.

Data

1:1 heterodimer verified by nonreductive electrophoresis and MALS

ACROBiosystems has developed a series of homogeneous CD3 proteins with good bioactivity, which are verified as 1:1 heterodimer by nonreductive electrophoresis and MALS.


Fig.1 Human CD3E&CD3D Heterodimer Protein (Cat. No. CDD-H52Wa) on SDS-PAGE under reducing (R) and non-reducing(NR)condition and the purity of the protein is greater than 95%. The purity of the protein is more than 85% and around 80-90 kDa verified by SEC-MALS.

High binding ability and low batch-to-batch differences

These verified authentic 1:1 heterodimer proteins show high bioactivity in different applications. The products are homogenous with strict quality control to guarantee the minimal batch-to-batch differences.


Fig.2 Immobilized Biotinylated Human CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDD-H82W6) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a  (Cat. No. CDE-M120a) with a linear range of 0.2-6 ng/mL (QC tested), and batch differences EC50<0.0001 μg/mL.

Designed for different applications of drug development

These products are suitable for various applications at different stages of drug development, such as antibody immunotiter detection, biopanning, antibody screening, affinity characterization and clinical pharmacokinetic assays.

Application 1: Development and screening of antibody drugs

Fig.3 Immobilized Biotinylated Human CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDD-H82W6) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a  (Cat. No. CDE-M120a) with a linear range of 0.2-6 ng/mL.

Fig.4 Immobilized Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) at 1 μg/mL (100 μL/well) can bind Anti-CD3 antibody with a linear range of 0.2-6 ng/mL.


Application 2: Identification and quality control of antibody drugs

Fig.5 Immobilized Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a  (Cat. No. CDE-M120a) with a linear range of 0.2-6 ng/mL.

Fig.6 Immobilized Human CD3E&CD3D Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. CDD-H5255) at 1 μg/mL (100 μL/well) can bind Bispecific BCMA×CD3 T cell-engaging Antibody with a linear range of 0.8-6 ng/mL.

Fig.7 Biotinylated Human CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDD-H82W6) captured on Biotin CAP - Series S sensor Chip can bind Anti-Human CD3 Antibody, Mouse IgG2a  with an affinity constant of 22.5 nM as determined in a SPR assay (Biacore T200) .

Fig.8 Bispecific T-cell Engager (CD3 X BCMA) immobilized on CM5 Chip can bind Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) with an affinity constant of 31.8 nM as determined in a SPR assay (Biacore T200).

Application 3: Clinical PK assay

Fig.9 Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3 X BCMA) in 10% human serum and then add Biotinylated Human CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDD-H82W6) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 15 ng/mL.

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message